ProPhase Labs
ProPhase Labs (OTC: PRPH) is a micro-cap biotech operating DTC whole genome sequencing via Nebula Genomics/DNA Complete, the BE-Smart esophageal cancer diagnostic, and TK Supplements consumer products, currently pursuing strategic alternatives including a reverse merger with ABL.
- Company typePublic
- Founded2018
- HeadquartersDoylestown, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingServices
What ProPhase Labs does
ProPhase Labs is a publicly traded, diversified next-generation biotech, genomics, and consumer products company that operates through three core segments. First, through wholly-owned subsidiaries Nebula Genomics and DNA Complete, the company offers direct-to-consumer whole genome sequencing at three subscription tiers (Essential 1x, Pro 30x, Elite 100x WGS) with up to 350 personalized health and ancestry reports. Second, through ProPhase BioPharma, the company holds the BE-Smart esophageal cancer diagnostic — a CLIA-certified, CAP-accredited 8-protein mass spectrometry assay developed with Mayo Clinic for risk stratification of Barrett's Esophagus patients — plus worldwide exclusive licenses for Linebacker LB-1/LB-2 (PIM kinase cancer co-therapeutics) and Equivir antivirals. Third, TK Supplements distributes consumer health products (Legendz XL, Triple Edge XL) through Walmart, Walgreens, CVS, and Rite-Aid.
The company was historically a consumer health products business (Cold-EEZE was sold to Mylan for $50M); under Chairman and CEO Ted Karkus it pivoted into molecular diagnostics and genomics, acquiring Nebula Genomics for $14.6M in August 2021. That pivot peaked with COVID-19 diagnostic testing revenue of $122.6M in FY2022, followed by sequential contraction to $4.9M in FY2025 as testing demand evaporated. The diagnostics subsidiary filed Chapter 11 in September 2025; the manufacturing subsidiary (Pharmaloz) was divested in January 2025. Current revenue is generated entirely from genomic services and consumer supplements, while a separate Crown Medical Collections initiative pursues recovery of approximately $201.2M in gross COVID testing claims for estimated net recoveries of $50-60M.
The company is now operating in a strategic-alternatives posture: in December 2025 it signed a non-binding LOI for a reverse merger with European biotech Advanced Biological Laboratories (ABL) at a valuation of up to $30M, which would transfer approximately 76% ownership to ABL shareholders and shift the strategic center of gravity to Europe. Concurrently, it has initiated an active sale or strategic partnership process for BE-Smart with outreach to over 70 potential acquirers. The company trades on OTC Markets under ticker PRPH after being downlisted from Nasdaq, and disclosed an unsealed False Claims Act civil lawsuit in the Eastern District of New York.
ProPhase Labs firmographics
Firmographics- Name
- ProPhase Labs
- Legal name
- ProPhase Labs, Inc.
- Website
- https://prophaselabs.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ProPhase Labs (OTC: PRPH) is a micro-cap biotech operating DTC whole genome sequencing via Nebula Genomics/DNA Complete, the BE-Smart esophageal cancer diagnostic, and TK Supplements consumer products, currently pursuing strategic alternatives including a reverse merger with ABL.
- Ownership category
- akta.pro rank
ProPhase Labs industry classification
Industry- Product category
- Diversified Biotech and Genomics
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Proteomics & Mass Spectrometry Services (HLAGANAB)
- akta.pro secondary industries
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Proteomics & Biomarker Analytical Testing (HLAGADAG), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where ProPhase Labs is headquartered
LocationHeadquarters
- HQ city
- Doylestown
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
ProPhase Labs business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Others
Revenue model
- Genomic Products and Services: Whole genome sequencing direct-to-consumer products through Nebula Genomics and DNA Complete, including subscription services for ongoing updates and personalized health reports
- Consumer Products: Sales of TK Supplements products including Legendz XL and Triple Edge XL through retail channels (Walmart, Walgreens, CVS, Rite-Aid) and online
- Crown Medical Collections: Recovery of unpaid and underpaid COVID-19 diagnostic testing claims, with estimated net recoveries of $50-60 million from approximately $201.2 million in gross claims
- BE-Smart Esophageal Cancer Test: Potential royalty or participation-based revenue streams from sale or strategic partnership of BE-Smart diagnostic test
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Essential tier with 1x whole genome sequencing and basic reports |
| Subscription | Annual | Pro tier with 30x whole genome sequencing and expanded reports |
| Subscription | Annual | Elite tier with 100x whole genome sequencing and comprehensive reports |
| Unit Pricing | Pay-as-you-go | BE-Smart esophageal cancer test |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
ProPhase Labs product offering
Product offeringCore offering
ProPhase Labs is a diversified biotech, genomics and consumer products company that sells direct-to-consumer whole genome sequencing services through Nebula Genomics and DNA Complete, develops the BE-Smart CLIA-certified esophageal cancer diagnostic test (an 8-protein mass spectrometry assay validated with Mayo Clinic), markets consumer dietary supplements under TK Supplements (Legendz XL, Triple Edge XL), and operates Crown Medical Collections to recover unpaid COVID-19 testing claims from over 250 insurance payors.
Product overview
ProPhase Labs operates as a diversified biotech, genomics and consumer products company with three core business segments: (1) Nebula Genomics and DNA Complete for whole genome sequencing and personalized genomic reports, (2) ProPhase BioPharma developing cancer therapeutics (Linebacker LB-1/LB-2) and antivirals (Equivir), and (3) TK Supplements consumer health products. The company also holds the BE-Smart esophageal cancer diagnostic test and is pursuing Crown Medical Collections for receivables recovery.
Differentiator
Problem solved
Functional benefit
Brands
- Nebula Genomics: Whole genome sequencing and personal genomics services
- DNA Complete
- ProPhase BioPharma
- TK Supplements
- BE-Smart
Products and services
- Nebula Genomics Whole genome sequencing platform providing consumers access to affordable DNA sequencing with over 300 personalized health and ancestry reports delivered through a secure online portal with subscription updates as new scientific discoveries emerge; co-founded by Dr. George Church.
- DNA Complete Direct-to-consumer whole genome sequencing platform offering three service tiers (Essential 1x WGS, Pro 30x WGS, Elite 100x WGS) with 175, 250, and 350 personalized health reports respectively; includes DNA Expand feature allowing consumers to upload existing DNA data for enhanced analysis across over 35 million genetic variants.
- BE-Smart Esophageal Cancer Test Laboratory-developed diagnostic test for risk stratification of Barrett's Esophagus patients to esophageal adenocarcinoma; runs on standard FFPE biopsy tissue with no additional procedures required; estimated reimbursement $1,000-$2,000 per test with a $7-14 billion annual addressable market based on 7 million U.S. upper endoscopies per year.
- Legendz XL TK Supplements male sexual enhancement dietary supplement trademarked product sold through Walmart, Walgreens, CVS, Rite-Aid and online.
- Triple Edge XL TK Supplements energy and stamina booster dietary supplement trademarked product sold through Walmart, Walgreens, CVS, Rite-Aid and online.
- Linebacker LB-1 and LB-2 Modified polyphenol therapeutic compounds developed under worldwide exclusive license from Global BioLife, Inc., targeting PIM kinase for cancer co-therapy combinations with Paclitaxel, Doxorubicin, Topotecan and Cisplatin; under two-year collaborative research agreement with Dana-Farber Cancer Institute and Harvard Medical School across hepatic, colon and breast cancer cell lines.
- Equivir Broad-based antiviral dietary supplement under worldwide exclusive license from Global BioLife, Inc.; includes an Equivir G prescription variant being commercialized through licensing agreements.
- Crown Medical Collections Specialized medical claims collection service pursuing recovery of unpaid and underpaid COVID-19 diagnostic testing claims; covers approximately $201.2 million in gross claims across 649,205 individual claims and 194 open matters with approximately $79.9 million in active settlement negotiations across 250+ insurance payors, with estimated net recoveries of $50-60 million.
Quantifiable outcome
- BE-Smart demonstrated very high sensitivity for progression prediction in Mayo Clinic pilot study
- +4 more outcomes
Companies that use ProPhase Labs
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
ProPhase Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ProPhase Labs partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Advanced Biological Laboratories (ABL)coreNon-binding LOI for proposed reverse merger where ABL shareholders would own approximately 76% of combined entity at valuation of up to $30 million; includes potential $10 million special cash dividend and carve-out of approximately $50 million in receivables
- Certis OncologyminorPartnership using CertisAI Predictive Oncology Intelligence to determine which cancers Linebacker would be most effective against
- Mayo Clinic (Dr. Christopher Hartley)coreCollaboration with Mayo Clinic for continued development of BE-Smart Esophageal Pre-Cancer diagnostic screening test, yielding clinical evidence and publication supporting the 8-protein assay
- Dana-Farber Cancer Institute and Harvard Medical SchoolcoreTwo-year collaborative agreement to further research LB-1, with studies focused on identifying most effective combination of cancer cell lines and agents; initial focus on hepatic, colon and breast cancer
- Dr. George ChurchcoreCo-founder and Advisory Board member of Nebula Genomics; Professor of Genetics at Harvard Medical School and Director of PersonalGenomes.org; pioneered development of multiple DNA sequencing methods
- mProbe, Inc.coreIndependent test lab utilized for BE-Smart test validation on over 200 human samples; precision health company utilizing clinical proteomics in oncology
- Dr. Joe AbdocoreMolecular oncology scientist with 18+ years experience; member of Clinical Science Advisory Board for ProPhase Labs and ProPhase Biopharma; Vice President of Clinical Diagnostics at Oxford BioDynamics
- RedChip CompaniescoreInvestor relations firm engaged to lead investor relations efforts and increase visibility with institutional and retail investors
- Renmark Financial CommunicationsminorContinues hosting earnings calls and virtual road shows for ProPhase Labs
- Crown Medical Collections, LLCcoreSpecialized medical collections firm serving as special counsel to ProPhase's laboratory subsidiaries for recovery of COVID-19 testing claims
- WestPark CapitalminorSales agreement relating to shares for at-the-market offering
Scale indicators15 records
Recent moves10 records
Expansion highlights5 records
ProPhase Labs competitors and assessment
Company assessmentDirect peers
- Ancestry: Largest DTC genealogy and consumer genomics brand; competes with Nebula/DNA Complete in the consumer DNA testing and ancestry category.
- mProbe: Clinical proteomics company specializing in oncology biomarker assays; partnered with ProPhase on BE-Smart validation and operates in the same proteomics-driven cancer testing niche.
- 23andMe: Direct-to-consumer genetic testing company offering ancestry and health reports, directly comparable to Nebula Genomics and DNA Complete in the consumer WGS/genotyping category.
- Exact Sciences: Commercial-stage cancer diagnostics company (Cologuard, Oncotype DX) with strong gastroenterology channel overlap to BE-Smart and a similar biomarker-based testing business model.
- Castle Biosciences: Specialized cancer diagnostics company commercializing proprietary tissue-based tests; comparable to BE-Smart's CLIA-certified LDT positioning and oncology risk-stratification model.
- Veritas Genetics: Whole genome sequencing company with consumer and clinical offerings, directly comparable to Nebula Genomics/DNA Complete in the WGS-as-a-service category.
- Color: Clinical and population-scale genetic testing platform offering hereditary cancer and whole genome tests; competes with Nebula/DNA Complete in DTC-adjacent and clinical genomics.
- Oxford BioDynamics: Molecular diagnostics company using proprietary biomarker platforms in oncology; comparable to BE-Smart's proteomics/molecular test positioning, and home to ProPhase advisor Dr. Joe Abdo.
- MyHeritage: DTC ancestry and health genetic testing company serving global consumers; directly comparable to Nebula/DNA Complete in DTC genetic reports.
Broad incumbents
- Guardant Health: Established liquid biopsy and oncology diagnostics company with broader cancer portfolio; comparable as a cancer diagnostics incumbent pursuing biomarker-led oncology tests similar to BE-Smart.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
ProPhase Labs social profiles
Digital presenceProPhase Labs compliance and trust
Trust signalCompliance4 records
ProPhase Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProPhase Labs leadership team
Management profileNumber of profiles
Profiles7 records
ProPhase Labs subsidiaries and ownership
Company hierarchySubsidiaries5 records
ProPhase Labs funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProPhase Labs M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProPhase Labs
What does ProPhase Labs do?
ProPhase Labs is a diversified biotech, genomics and consumer products company that sells direct-to-consumer whole genome sequencing services through Nebula Genomics and DNA Complete, develops the BE-Smart CLIA-certified esophageal cancer diagnostic test (an 8-protein mass spectrometry assay validated with Mayo Clinic), markets consumer dietary supplements under TK Supplements (Legendz XL, Triple Edge XL), and operates Crown Medical Collections to recover unpaid COVID-19 testing claims from over 250 insurance payors.
Is ProPhase Labs a public or private company?
ProPhase Labs is a public company. It is classified as public and is currently operating.
When was ProPhase Labs founded?
ProPhase Labs was founded in 2018. It employs 51 to 100 people.
Where is ProPhase Labs based?
ProPhase Labs is headquartered in Doylestown, United States, in the North America region.
How does ProPhase Labs make money?
Four revenue lines are on record. Genomic Products and Services are the primary driver. The others are consumer Products, crown Medical Collections and BE-Smart Esophageal Cancer Test.
Who are ProPhase Labs's main competitors?
Direct peers on record are Ancestry, mProbe, 23andMe, Exact Sciences, Castle Biosciences, Veritas Genetics, Color, Oxford BioDynamics and MyHeritage. Guardant Health is listed as a broad incumbent.
Does ProPhase Labs have an API?
No public API is recorded for ProPhase Labs.
What industry is ProPhase Labs in?
ProPhase Labs's product category is Diversified Biotech and Genomics. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 8071.